Journal
EUROSURVEILLANCE
Volume 27, Issue 18, Pages 8-13Publisher
EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2022.27.18.2200322
Keywords
-
Categories
Funding
- Swedish Research Council (VR) [2019-00198, 2021-04665]
- Sweden's Innovation Agency (Vinnova) [2021-02648]
- Swedish Research Council
- Governmental Funds for Clinical Research (ALF)
- Swedish Research Council for Health, Working life and Welfare (Forte) [2020-00962]
- Lund University
- Formas [2020-00962] Funding Source: Formas
- Forte [2020-00962] Funding Source: Forte
- Swedish Research Council [2021-04665] Funding Source: Swedish Research Council
Ask authors/readers for more resources
We compared the effectiveness of vaccines against severe COVID-19 during the period of December 2021 to March 2022, when Omicron BA.1 and BA.2 variants were dominant in Scania county, Sweden. The effectiveness remained above 80% for individuals with at least three vaccine doses, but decreased to 54% for those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination appears to be necessary to maintain sufficient protection.
We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA. 2. Booster vaccination seems necessary to maintain sufficient protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
